b'A novel approach in pediatric ADHD (ages 6-17) 1 .The only NCE approved for the treatment of ADHD in over a decade! 1,2Actor portrayal.More control1,3Rethink ADHD Symptom Control INDICATION CONTRAINDICATIONSQelbree is indicated for the treatment of Attention-De cit/ Concomitant administration of a monoamine oxidase inhibitor Hyperactivity Disorder (ADHD) in pediatric patients ages 6 to 17. (MAOI), or dosing within 14 days after discontinuing an MAOI, IMPORTANT SAFETY INFORMATION because of an increased risk of hypertensive crisis Concomitant administration of sensitive CYP1A2 substrates or WARNING: SUICIDAL THOUGHTS AND BEHAVIORS CYP1A2 substrates with a narrow therapeutic rangeIn clinical studies, higher rates of suicidal thoughts and behaviorsWARNING & PRECAUTIONwere reported in pediatric patients with ADHD treated withSuicidal Thoughts and Behaviors: Closely monitor all Qelbree-treated Qelbree than in patients treated with placebo. Closely monitorpatients for clinical worsening and emergence of suicidal thoughts all Qelbree-treated patients for clinical worsening and forand behaviors, especially during the initial few months of drug emergence of suicidal thoughts and behaviors. therapy, and at times of dosage changes. Abbreviation: NCE, new chemical entity.REFERENCES:1. Qelbree [package insert]. Rockville, MD: Supernus Pharmaceuticals, Inc. 2. Vyvanse [package insert]. Lexington, MA: Shire US. 3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Washington, DC: American Psychiatric Publishing; 2013. Please see the brief summary of full Prescribing Information on adjacent pages, or visit QelbreeHCP.com.Qelbree and Rethink ADHD Symptom Control are trademarks of Supernus Pharmaceuticals, Inc. 2021 Supernus Pharmaceuticals, Inc. All rights reserved. QBE.2021-0102QBE.2021-0102 HCP Girl Wordcloud Ad_USMed_M01.indd 1 11/22/21 7:17 AM'